Wed, August 18, 2010
Tue, August 17, 2010
Mon, August 16, 2010
Fri, August 13, 2010
Thu, August 12, 2010
Wed, August 11, 2010
Tue, August 10, 2010
Mon, August 9, 2010
Fri, August 6, 2010
Thu, August 5, 2010
Wed, August 4, 2010
Tue, August 3, 2010
Mon, August 2, 2010
Fri, July 30, 2010
Thu, July 29, 2010
Wed, July 28, 2010
Tue, July 27, 2010

Inspire Announces Webcast of Presentation at Bank of America Merrill Lynch Specialty Pharmaceuticals Conference

  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. -lynch-specialty-pharmaceuticals-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

DURHAM, N.C.--([ BUSINESS WIRE ])--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Adrian Adams, President and CEO, will present at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference Thursday, August 12, 2010 at 3:40 pm ET in Southampton, NY.

The webcast of the presentation will be available on Inspire's web site at [ www.inspirepharm.com ]. An archived version of the webcast presentation will also be available through this link for a limited time following the conference.

About Inspire

Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspirea™s goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical, scientific and commercial expertise. The most advanced compounds in Inspirea™s clinical pipeline are denufosol tetrasodium for cystic fibrosis and PROLACRIAa" (diquafosol tetrasodium ophthalmic solution) 2% for dry eye, which are both in Phase 3 development, and AZASITE®(azithromycin ophthalmic solution) 1% for blepharitis, which is in Phase 2 development. Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% for dry eye. For more information, visit [ www.inspirepharm.com ].